Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2021

View Archived Issues

Polymer-mediated "immunocloaking" - A new paradigm for combating transplant rejection?

Phase I trial begins for DVX-201 allogeneic NK cells in COVID-19 patients

Trial starts enrollment to assess LY-3361237 in patients with psoriasis

TYK2 inhibitor NDI-034858 enters phase II investigation for plaque psoriasis

MedImmune patents new ADCs for cancer

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Apeximmune Therapeutics describes anti-B7-H4 constructs for cancer

Primary endpoint not met in phase II trial of trimodulin in patients with severe COVID-19

Lomecel-B improves physical function in phase IIb study in patients with aging frailty

Phase I study of tyrosine kinase 2 inhibitor ICP-332 begins in China

Phase Ib data reported for ITPP in patients with hepatopancreatobiliary tumors

SPTBN1 genetic variants found to be associated with neurodevelopmental syndrome

Leptin linked to severity of COVID-19

Enanta's HBV treatment begins phase I study

LAVA Therapeutics cleared to initiate clinical trial of LAVA-1207

FDA lifts clinical hold on trial of Danon disease treatment RP-A501

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...